Literature DB >> 34321545

Implementation of whole genome sequencing for tuberculosis diagnostics in a low-middle income, high MDR-TB burden country.

Monica Vogel1, Christian Utpatel2,3, Caroline Corbett1, Thomas A Kohl2,3, Altyn Iskakova4, Sevim Ahmedov5, Uladzimir Antonenka1, Viola Dreyer2,3, Ainura Ibrahimova6, Chynara Kamarli7, Dilorom Kosimova6, Vanessa Mohr2,3, Evgeni Sahalchyk1, Meerim Sydykova4, Nagira Umetalieva1, Abdylat Kadyrov8, Gulmira Kalmambetova4, Stefan Niemann2,3, Harald Hoffmann9,10.   

Abstract

Whole genome sequencing (WGS) is revolutionary for diagnostics of TB and its mutations associated with drug-resistances, but its uptake in low- and middle-income countries is hindered by concerns of implementation feasibility. Here, we provide a proof of concept for its successful implementation in such a setting. WGS was implemented in the Kyrgyz Republic. We estimated needs of up to 55 TB-WGS per week and chose the MiSeq platform (Illumina, USA) because of its capacity of up to 60 TB-WGS per week. The project's timeline was completed in 93-weeks. Costs of large equipment and accompanying costs were 222,065 USD and 8462 USD, respectively. The first 174 WGS costed 277 USD per sequence, but this was skewed by training inefficiencies. Based on real prices and presuming optimal utilization of WGS capacities, WGS costs could drop to 167 and 141 USD per WGS using MiSeq Reagent Kits v2 (500-cycles) and v3 (600-cycles), respectively. Five trainings were required to prepare the staff for autonomous WGS which cost 48,250 USD. External assessment confirmed excellent performance of WGS by the Kyrgyz laboratory in an interlaboratory comparison of 30 M. tuberculosis genomes showing complete agreeance of results.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34321545     DOI: 10.1038/s41598-021-94297-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  1 in total

1.  Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.

Authors:  Helen Cox; Galo A Goig; Zubeida Salaam-Dreyer; Anzaan Dippenaar; Anja Reuter; Erika Mohr-Holland; Johnny Daniels; Patrick G T Cudahy; Mark P Nicol; Sonia Borrell; Miriam Reinhard; Anna Doetsch; Christian Beisel; Sebastien Gagneux; Robin M Warren; Jennifer Furin
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.